Basiliximab scFv-Transferrin Fusion for Barrier-Penetrating Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Many antibodies face challenges in crossing biological barriers such as the blood-brain barrier and blood-eye barrier, and entering cancerous cells due to their size and lack of specific targeting mechanisms, limiting their efficacy and application in certain diseases.
Innovation Solution
A single-chain variable fragment (scFv) is designed to bind with the N-methyl lobe of the transferrin protein, utilizing transferrin receptor-mediated endocytosis to enhance cellular uptake, and incorporating cleavable linkers that respond to specific cellular environments for targeted delivery and release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If whole antibodies are used for therapy, then effector functions and half-life are improved, but penetration across biological barriers and cellular uptake are reduced
Solution Approach 1:
The antibody is segmented into its functional components: the scFv retains antigen-binding capability while the Fc region is removed. This segmentation allows the therapeutic agent to maintain efficacy through the variable regions while reducing size-related barriers to penetration and cellular uptake.
Solution Approach 2:
The Fc region is extracted from the complete antibody structure, leaving only the scFv portion that contains the antigen-binding variable regions. This extraction eliminates the size and structural barriers imposed by the Fc region while preserving the therapeutic binding function.
2Length of moving object
If scFv is used instead of whole antibody, then penetration and cellular uptake are improved, but effector functions and half-life are reduced
Solution Approach 1:
Transferrin acts as an intermediary that mediates cellular uptake of the scFv through transferrin receptor-mediated endocytosis. This intermediary mechanism compensates for the reduced cellular uptake capability of bare scFv, allowing efficient entry into target cells without requiring the full antibody structure.
Solution Approach 2:
The scFv is chemically conjugated to transferrin, fundamentally changing its physical and biological parameters. This conjugation modifies the molecular properties to enable receptor-mediated endocytosis, thereby extending cellular uptake efficiency and potentially improving half-life through the transferrin cycle.
3Measurement precision
If antibodies are designed for specific target binding, then binding specificity is improved, but ability to cross biological barriers is reduced
Solution Approach 1:
The scFv with high binding specificity is merged with transferrin, which provides barrier-penetration capabilities through receptor-mediated transcytosis. This combination merges the advantages of specific antigen binding with the ability to cross biological barriers via the transferrin receptor pathway.
Solution Approach 2:
Transferrin serves as a mediator that facilitates barrier crossing while the scFv maintains its specific target binding function. The intermediary transferrin handles the barrier penetration task through its natural receptor interaction, allowing the scFv to focus on specific antigen recognition without being hindered by barrier constraints.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The scFv-conjugate achieves enhanced penetration across biological barriers, improves therapeutic efficacy by reducing off-target effects, and ensures prolonged interaction with target cells, thereby increasing treatment effectiveness.
Implementation Method 1
A single-chain variable fragment (scFv) is designed to bind with the N-methyl lobe of the transferrin protein, utilizing transferrin receptor-mediated endocytosis to enhance cellular uptake
Implementation Method 2
incorporating cleavable linkers that respond to specific cellular environments for targeted delivery and release
Data Source
AI summary
The efficacy and indication of basiliximab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.